Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
NCT00451763
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Retina
Telangiectasis
Interventions
DRUG:
Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)
Sponsor
University of Sao Paulo
Collaborators
[object Object]